vantictumab
mAbexperimental
Vantictumab is a human IgG2 monoclonal antibody designed for the treatment of cancer. — Wikipedia
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2011 (NCT01345201)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Frizzled-10Immunity, passive
FZD10 immunity, passive
- Frizzled-7ANTAGONIST
FZD7 antagonist
mAB
- Frizzled-8ANTAGONIST
FZD8 antagonist
mAB
- Frizzled-5ANTAGONIST
FZD5 antagonist
mAB
- Frizzled-2ANTAGONIST
FZD2 antagonist
mAB
- Frizzled-1ANTAGONIST
FZD1 antagonist
mAB
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVantictumab ↗
- ChEMBLCHEMBL2364652 ↗
Also known as
- omp-18r5
- omp-18r5
- omp-18r5
- vantictumab
- vantictumab
- vantictumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01957007 | Phase 1 | Sep 1, 2013 | Mereo BioPharma |
| NCT01973309 | Phase 1 | Sep 1, 2013 | Mereo BioPharma |
| NCT02005315 | Phase 1 | Sep 1, 2013 | Indiana University, Mereo BioPharma |
| NCT01345201 | Phase 1 | May 1, 2011 | Mereo BioPharma |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mereo BioPharma | For profit | 4 | 4 | 1 | 2011 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1